Skip to content Skip to sidebar Skip to footer
Illustration of scientists using molecular models and lab equipment, with Alphabet and Isomorphic Labs branding and a $5B graphic.

Alphabet’s drug-design company has raised $7.7 billion across three announced rounds. The next milestone is not another financing. It is a first human trial.

Isomorphic Labs raised $5 billion in a Series C announced Nov. 17, giving Alphabet’s AI drug-design company more than twice the capital it raised in May. Greenoaks and Sequoia Capital co-led the round, Andreessen Horowitz joined as a new backer, and Alphabet (NASDAQ: GOOGL, GOOG) made what Isomorphic described as a continued significant investment. The company plans to expand its proprietary drug-design platform and advance its first therapeutic programs toward clinical trials. The bullish case is not that artificial intelligence can make biology predictable. It is that better predictions could help drugmakers decide sooner which candidates deserve expensive experiments. If Isomorphic can do that repeatedly, the value will show up not in how many molecules its software can propose, but in how many promising ones its scientists can move forward. The financing buys time to find out. Biology, notoriously, does not read term sheets.

Three funding rounds, one much bigger test

The Series C follows a $2.1 billion Series B led by Thrive Capital in May 2026 and a $600 million first external round in March 2025. That puts Isomorphic’s three announced rounds at $7.7 billion, with $7.1 billion announced in roughly six months. Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund all returned for the latest round. The Series C announcement did not disclose a post-money valuation. The $5 billion is capital raised, not a price tag for the company. What makes the raise interesting is what it lets Isomorphic pursue at the same time. The company can keep improving IsoDDE, its proprietary drug-design engine, while advancing its own candidates and carrying out research with pharmaceutical partners. The collaborations offer a way to test the platform against problems selected by established drugmakers. The in-house pipeline poses a tougher and potentially more valuable question: Can Isomorphic turn its own research decisions into medicines it has a larger stake in?

AlphaFold gave Isomorphic a head start. It did not give it a drug.

Isomorphic grew out of work at Google DeepMind in 2021. The two teams later developed AlphaFold 3, a model that predicts three-dimensional structures of biomolecular complexes, helping researchers see how a protein and a potential drug molecule might fit together. Founder and CEO Demis Hassabis shared the 2024 Nobel Prize in Chemistry for work on protein structure prediction. IsoDDE is the company’s broader, proprietary drug-design platform, not simply another name for AlphaFold. That distinction matters. A structural prediction can give scientists a better hypothesis and help them decide what to test first. It cannot tell them whether a candidate will be safe at a useful dose or deliver a meaningful benefit in patients. For many following AI drug discovery, the most persuasive evidence will be a candidate that makes it into human testing, followed by data that justify a larger study. A faster route to the wrong molecule is still the wrong route.]

Lilly, Novartis and Johnson & Johnson put the platform to work

The strongest commercial evidence so far comes from drugmakers paying to use the approach in research. The original Eli Lilly and Novartis agreements announced in January 2024 called for a combined $82.5 million upfront, with up to $2.9 billion more in performance-based milestones. Those milestones are contingent, not booked revenue, and the upfront payments are separate from the venture financing.

  • Eli Lilly and Company (NYSE: LLY) agreed to $45 million upfront for a multi-target small-molecule discovery collaboration. Isomorphic was eligible for up to $1.7 billion in performance-based milestones under the original agreement.
  • Novartis AG (NYSE: NVS; SIX: NOVN) agreed to $37.5 million upfront, funding for select research costs, and up to $1.2 billion in performance-based milestones under its original agreement. In February 2025, the companies expanded the collaboration to add up to three research programs on the same financial terms as the original deal. A partner widening the scope after a year of work is a more telling signal than a partner signing on in the first place..
  • Johnson & Johnson (NYSE: JNJ) joined in January 2026 with a multi-target collaboration that extends to large molecules and biologics. That gives Isomorphic a chance to show its approach can travel beyond the small-molecule work that anchored its first two pharma deals.

What could make the bet pay off for Alphabet?

Isomorphic Labs has no standalone public ticker. Alphabet offers indirect exposure through GOOGL and GOOG, but neither share class is a pure play on AI drug discovery. The strategic upside for Alphabet is the chance to capture value from AI through drug candidates and pharmaceutical partnerships, not just through software and computing. The financing makes that opportunity more credible; it does not yet make it material to Alphabet’s earnings. The first catalyst to watch is a named candidate entering human trials, with a disclosed indication and study design. That would show Isomorphic can move a program from computational design into clinical development. Early safety and dosing data would help determine whether that particular molecule deserves further study. A second program reaching the same stage, or a partner disclosing a meaningful development milestone, would do more to support the bigger claim that the platform can deliver repeatable results. The $5 billion round gives Isomorphic room to pursue that proof across more than one program. If the company can repeatedly turn better predictions into candidates worth testing in people, Alphabet will have backed something rarer than a well-funded AI company: a drug-discovery business with a measurable edge..

The Sources

  1. Isomorphic Labs: Series C investment announcement
  2. Bloomberg: Sequoia and Greenoaks lead Isomorphic Labs’ $5 billion financing
  3. SEC.gov: Alphabet Inc. fiscal 2025 Form 10-K
  4. Isomorphic Labs: $2.1 billion Series B announcement
  5. Isomorphic Labs: Series B press release and planned use of proceeds
  6. Isomorphic Labs: $600 million first external funding round
  7. Isomorphic Labs: Rational drug design with AlphaFold 3
  8. Isomorphic Labs: AlphaFold 3 research announcement
  9. Isomorphic Labs: Founding background and scientific advisory board announcement
  10. Isomorphic Labs: Demis Hassabis biography
  11. Isomorphic Labs: Original Eli Lilly and Novartis collaboration announcements
  12. Isomorphic Labs: Original Novartis collaboration terms
  13. Isomorphic Labs: Novartis collaboration expansion
  14. SEC.gov: Novartis AG fiscal 2025 Form 20-F
  15. Isomorphic Labs: Johnson & Johnson research collaboration
  16. SEC.gov: Johnson & Johnson fiscal 2025 Form 10-K
  17. Isomorphic Labs: Pharmaceutical partnerships overview

Disclosure: This article is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any security. Market data are subject to revision, and investors should conduct independent due diligence before making investment decisions. Investments may involve substantial risk, including the potential loss of the entire investment. Investors should conduct independent due diligence and consider their individual objectives and risk tolerance. See The Complete Disclosure via this link & at the top of the page.